Maravai LifeSciences Q2 Revenue USD 51.4 Million Vs. IBES Estimate USD 48.7 Million
MRVI•Full-year outlook
- FY revenue outlook: USD 205-215 million versus the IBES estimate of USD 210.4 million
- FY adjusted EBITDA outlook: USD 33-35 million versus the IBES estimate of USD 30.9 million
Q2 revenue and earnings
Aug. 6 (Reuters) - Maravai LifeSciences Q2 adjusted EBITDA was USD 8.7 million versus the IBES estimate of USD 3.05 million.
- Q2 net income: USD -21.6 million
